Teva Pharma Industries Stock Buy Hold or Sell Recommendation
| TEVA Stock | USD 16.78 0.21 1.27% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Teva Pharma Industries is 'Strong Sell'. Macroaxis provides Teva Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TEVA positions.
Check out Teva Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Teva and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Teva |
Execute Teva Pharma Buy or Sell Advice
The Teva recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Teva Pharma Industries. Macroaxis does not own or have any residual interests in Teva Pharma Industries or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Teva Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Teva Pharma Trading Alerts and Improvement Suggestions
| Teva Pharma generated a negative expected return over the last 90 days | |
| Teva Pharma Industries currently holds 20.15 B in liabilities with Debt to Equity (D/E) ratio of 2.27, implying the company greatly relies on financing operations through barrowing. Teva Pharma Industries has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Teva Pharma's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 15.85 B. Net Loss for the year was (615 M) with profit before overhead, payroll, taxes, and interest of 6.97 B. | |
| Teva Pharma has a strong financial position based on the latest SEC filings | |
| About 57.0% of Teva Pharma shares are owned by institutional investors | |
| Latest headline from bnnbloomberg.ca: British Columbia Can Mount Opioid Class Action, Canadas Top Court Says |
Teva Pharma Returns Distribution Density
The distribution of Teva Pharma's historical returns is an attempt to chart the uncertainty of Teva Pharma's future price movements. The chart of the probability distribution of Teva Pharma daily returns describes the distribution of returns around its average expected value. We use Teva Pharma Industries price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Teva Pharma returns is essential to provide solid investment advice for Teva Pharma.
| Mean Return | -0.14 | Value At Risk | -2.23 | Potential Upside | 2.51 | Standard Deviation | 1.77 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Teva Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Teva Stock Institutional Investors
| Shares | Slate Path Capital Lp | 2024-09-30 | 13.7 M | Millennium Management Llc | 2024-06-30 | 12.1 M | Pointstate Capital Lp | 2024-09-30 | 9.8 M | Geode Capital Management, Llc | 2024-09-30 | 8.8 M | Glenview Capital Management Llc | 2024-09-30 | 8.5 M | Renaissance Technologies Corp | 2024-09-30 | 8.1 M | Australiansuper Pty Ltd | 2024-09-30 | 7.9 M | Viking Global Investors Lp | 2024-09-30 | 7.6 M | Parsifal Capital Management, Lp | 2024-09-30 | 6.2 M | Fmr Inc | 2024-09-30 | 62.7 M | Blackrock Inc | 2024-06-30 | 43 M |
Teva Pharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 271M | 41M | 380M | (163M) | (147M) | (139.7M) | |
| Change In Cash | 734M | 202M | 21M | 636M | 393M | 412.7M | |
| Free Cash Flow | 419M | 638M | 236M | 1.0B | 842M | 1.5B | |
| Depreciation | 1.8B | 416M | 1.6B | 1.3B | 1.2B | 767.4M | |
| Other Non Cash Items | 471M | 6.5B | 714M | 2.4B | 1.1B | 1.6B | |
| Capital Expenditures | 119M | 578M | 562M | 548M | 526M | 486.4M | |
| Net Income | 76M | (4.1B) | 456M | (2.4B) | (615M) | (584.3M) | |
| End Period Cash Flow | 2.0B | 2.2B | 2.2B | 2.8B | 3.2B | 3.4B | |
| Investments | 343M | 67M | 172M | 656M | 968M | 1.0B | |
| Net Borrowings | (1.9B) | (1.9B) | (1.7B) | (1.4B) | (1.2B) | (1.2B) | |
| Change To Netincome | 1.9B | 6.9B | 729M | 1.4B | 1.2B | 1.2B |
Teva Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Teva Pharma or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Teva Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Teva stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.1 | |
β | Beta against Dow Jones | -0.36 | |
σ | Overall volatility | 1.79 | |
Ir | Information ratio | -0.15 |
Teva Pharma Volatility Alert
Teva Pharma Industries exhibits very low volatility with skewness of -0.39 and kurtosis of 3.39. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Teva Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Teva Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Teva Pharma Fundamentals Vs Peers
Comparing Teva Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Teva Pharma's direct or indirect competition across all of the common fundamentals between Teva Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Teva Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Teva Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Teva Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Teva Pharma to competition |
| Fundamentals | Teva Pharma | Peer Average |
| Return On Equity | -0.18 | -0.31 |
| Return On Asset | 0.0556 | -0.14 |
| Profit Margin | (0.06) % | (1.27) % |
| Operating Margin | 0.23 % | (5.51) % |
| Current Valuation | 34.73 B | 16.62 B |
| Shares Outstanding | 1.13 B | 571.82 M |
| Shares Owned By Institutions | 57.16 % | 39.21 % |
| Number Of Shares Shorted | 21.19 M | 4.71 M |
| Price To Earning | 15.67 X | 28.72 X |
| Price To Book | 3.10 X | 9.51 X |
| Price To Sales | 1.12 X | 11.42 X |
| Revenue | 15.85 B | 9.43 B |
| Gross Profit | 6.97 B | 27.38 B |
| EBITDA | 433 M | 3.9 B |
| Net Income | (615 M) | 570.98 M |
| Cash And Equivalents | 2.22 B | 2.7 B |
| Cash Per Share | 2.00 X | 5.01 X |
| Total Debt | 20.15 B | 5.32 B |
| Debt To Equity | 2.27 % | 48.70 % |
| Current Ratio | 0.99 X | 2.16 X |
| Book Value Per Share | 5.35 X | 1.93 K |
| Cash Flow From Operations | 1.37 B | 971.22 M |
| Short Ratio | 3.16 X | 4.00 X |
| Earnings Per Share | (0.85) X | 3.12 X |
| Price To Earnings To Growth | 1.29 X | 4.89 X |
| Target Price | 22.36 | |
| Number Of Employees | 37 K | 18.84 K |
| Beta | 0.87 | -0.15 |
| Market Capitalization | 18.77 B | 19.03 B |
| Total Asset | 43.48 B | 29.47 B |
| Retained Earnings | (13.53 B) | 9.33 B |
| Working Capital | 238 M | 1.48 B |
| Current Asset | 18.4 B | 9.34 B |
Note: Disposition of 12872 shares by Shalev Varda of Teva Pharma subject to Rule 16b-3 [view details]
Teva Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Teva . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Teva Pharma Buy or Sell Advice
When is the right time to buy or sell Teva Pharma Industries? Buying financial instruments such as Teva Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Teva Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Airlines Thematic Idea Now
Airlines
Domestic and international airlines and airline services. The Airlines theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Airlines Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Teva Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.85) | Revenue Per Share 14.879 | Quarterly Revenue Growth 0.125 | Return On Assets 0.0556 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.